Review Article
An Insight into the “-Omics” Based Engineering of Streptomycetes for Secondary Metabolite Overproduction
Table 2
Methodologies used to overproduce drugs using engineered metabolic networks approach.
| Strains | Drugs | Approach | Methodologies |
| S. rimosus M4018 | Oxytetracycline | Engineered metabolic networks | Deletion of zwf1 and zwf2 genes improve the production of oxytetracycline | S. roseosporus | Daptomycin | Engineered metabolic networks | Over-expression of zwf2 gene improve the production of daptomycin | S. lividans | Actinorhodin and undecylprodigiosin | Engineered metabolic networks | Deletion of zwf1 or zwf2 improved actinorhodin and undecylprodigiosin production | S. coelicolor A3 (2) | Actinorhodin and undecylprodigiosin | Engineered metabolic networks | Deletion of pfkA2 (phosphofructokinase) gene improve the production of actinorhodin and undecylprodigiosin | S. noursei NRRL 5126 | ε-Poly-l-Lysine | Engineered metabolic networks | Supplementation of citric acid and L-Asp increases poly-ε-lysine production | S. tsukubaensis | FK506 (tacrolimus) | Engineered metabolic networks | Enhancing the biosyntheses of methoxymalonyl-ACP and allylmalonyl-CoA together with optimized glucose concentrations enhances the FK506 production | S. peucetius ATCC 27952 | Doxorubicin | Engineered metabolic networks | Over-expression of potential biosynthetic sugar genes and glycosyltransferase enhanced doxorubicin production |
|
|